Pediatrix Medical Group, Inc. Financials
This page shows Pediatrix Medical Group, Inc. (MD) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 18 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Pediatrix Medical Group, Inc. has an operating margin of 10.9%, meaning the company retains $11 of operating profit per $100 of revenue. This results in a moderate score of 46/100, indicating healthy but not exceptional operating efficiency. This is up from -3.4% the prior year.
Pediatrix Medical Group, Inc.'s revenue declined 4.9% year-over-year, from $2.0B to $1.9B. This contraction results in a growth score of 25/100.
Pediatrix Medical Group, Inc. carries a low D/E ratio of 0.66, meaning only $0.66 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 89/100, indicating a strong balance sheet with room for future borrowing.
Pediatrix Medical Group, Inc.'s current ratio of 1.66 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 29/100, which could limit financial flexibility.
Pediatrix Medical Group, Inc.'s ROE of 19.1% shows moderate profitability relative to equity, earning a score of 54/100. This is up from -13.0% the prior year.
Pediatrix Medical Group, Inc. scores 2.03, placing it in the grey zone between 1.81 and 2.99. This signals moderate financial risk that warrants monitoring.
Pediatrix Medical Group, Inc. passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), all 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Pediatrix Medical Group, Inc. generates $1.64 in operating cash flow ($271.1M OCF vs $165.4M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Pediatrix Medical Group, Inc. earns $5.8 in operating income for every $1 of interest expense ($208.8M vs $36.0M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
Pediatrix Medical Group, Inc. generated $1.9B in revenue in fiscal year 2025. This represents a decrease of 4.9% from the prior year.
Pediatrix Medical Group, Inc.'s EBITDA was $230.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 732.1% from the prior year.
Pediatrix Medical Group, Inc. reported $165.4M in net income in fiscal year 2025. This represents an increase of 266.9% from the prior year.
Cash & Balance Sheet
Pediatrix Medical Group, Inc. held $375.2M in cash against $570.5M in long-term debt as of fiscal year 2025.
Pediatrix Medical Group, Inc. had 83M shares outstanding in fiscal year 2025. This represents a decrease of 3.3% from the prior year.
Margins & Returns
Pediatrix Medical Group, Inc.'s operating margin was 10.9% in fiscal year 2025, reflecting core business profitability. This is up 14.3 percentage points from the prior year.
Pediatrix Medical Group, Inc.'s net profit margin was 8.6% in fiscal year 2025, showing the share of revenue converted to profit. This is up 13.6 percentage points from the prior year.
Pediatrix Medical Group, Inc.'s ROE was 19.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 32.0 percentage points from the prior year.
Capital Allocation
Pediatrix Medical Group, Inc. spent $86.7M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 4990.0% from the prior year.
MD Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $493.8M+0.2% | $492.9M+5.1% | $468.8M+2.3% | $458.4M-8.8% | $502.4M-1.7% | $511.2M+1.4% | $504.3M+1.9% | $495.1M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $65.7M+8.0% | $60.8M+9.1% | $55.7M-4.9% | $58.6M-7.8% | $63.6M+9.3% | $58.1M+2.8% | $56.6M-6.0% | $60.2M |
| Operating Income | $48.8M-28.3% | $68.1M+13.7% | $59.9M+86.5% | $32.1M-18.3% | $39.3M+16.2% | $33.8M+121.4% | -$157.7M-1092.5% | $15.9M |
| Interest Expense | $8.7M-2.2% | $8.9M-2.1% | $9.1M-0.3% | $9.2M-5.7% | $9.7M-4.1% | $10.1M-1.8% | $10.3M-2.7% | $10.6M |
| Income Tax | $11.9M-25.9% | $16.1M+2.3% | $15.7M+113.6% | $7.4M+158.2% | $2.8M-50.8% | $5.8M+139.4% | -$14.7M-488.0% | $3.8M |
| Net Income | $33.7M-53.0% | $71.7M+82.6% | $39.3M+89.3% | $20.7M-32.0% | $30.5M+56.8% | $19.4M+112.7% | -$153.0M-3892.4% | $4.0M |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
MD Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $2.2B+2.2% | $2.2B+4.6% | $2.1B+5.4% | $2.0B-7.4% | $2.2B+3.7% | $2.1B+4.1% | $2.0B-8.0% | $2.2B |
| Current Assets | $763.5M+6.5% | $717.2M+17.0% | $613.0M+24.7% | $491.7M-23.1% | $639.6M+21.1% | $528.2M+23.1% | $429.2M+0.6% | $426.5M |
| Cash & Equivalents | $375.2M+10.3% | $340.1M+51.3% | $224.7M+127.1% | $99.0M-57.0% | $229.9M+121.5% | $103.8M+435.2% | $19.4M+142.6% | $8.0M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $229.7M-0.6% | $231.1M-3.3% | $239.0M-1.5% | $242.5M-6.7% | $260.0M-9.4% | $286.9M+4.6% | $274.2M-3.4% | $283.7M |
| Goodwill | $1.3B+0.4% | $1.3B+1.0% | $1.2B0.0% | $1.2B0.0% | $1.2B+0.3% | $1.2B0.0% | $1.2B-11.1% | $1.4B |
| Total Liabilities | $1.4B+5.5% | $1.3B+3.2% | $1.3B+5.3% | $1.2B-13.2% | $1.4B+3.2% | $1.3B+4.3% | $1.3B-1.8% | $1.3B |
| Current Liabilities | $458.9M+16.9% | $392.5M+15.1% | $341.0M+25.8% | $271.1M-37.6% | $434.1M+16.4% | $373.1M+20.3% | $310.2M+25.4% | $247.3M |
| Long-Term Debt | $570.5M-1.1% | $577.2M-1.1% | $583.9M-1.1% | $590.5M-3.4% | $611.2M | N/A | N/A | N/A |
| Total Equity | $865.9M-2.8% | $890.7M+6.8% | $833.8M+5.6% | $789.2M+3.2% | $764.9M+4.4% | $732.5M+3.7% | $706.5M-17.5% | $856.2M |
| Retained Earnings | -$83.2M+28.8% | -$116.8M+38.0% | -$188.5M+17.2% | -$227.8M+8.3% | -$248.5M+10.9% | -$279.0M+6.5% | -$298.5M-105.2% | -$145.4M |
MD Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $114.1M-16.9% | $137.3M+0.1% | $137.2M+216.8% | -$117.5M-188.3% | $133.0M+44.8% | $91.8M-14.1% | $107.0M+185.4% | -$125.2M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | -$10.3M-255.7% | $6.6M+192.3% | -$7.2M+4.2% | -$7.5M-285.1% | -$1.9M+55.3% | -$4.3M+66.4% | -$12.9M+20.6% | -$16.2M |
| Financing Cash Flow | -$68.6M-140.3% | -$28.6M-570.6% | -$4.3M+29.4% | -$6.0M-21.6% | -$5.0M-61.6% | -$3.1M+96.3% | -$82.7M-208.5% | $76.2M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | $64.0M+206.9% | $20.9M+9884.2% | $209K-86.7% | $1.6M+144.0% | $643K+296.9% | $162K+1372.7% | $11K-98.8% | $887K |
MD Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | 9.9%-3.9pp | 13.8%+1.0pp | 12.8%+5.8pp | 7.0%-0.8pp | 7.8%+1.2pp | 6.6%+37.9pp | -31.3%-34.5pp | 3.2% |
| Net Margin | 6.8%-7.7pp | 14.5%+6.2pp | 8.4%+3.9pp | 4.5%-1.6pp | 6.1%+2.3pp | 3.8%+34.1pp | -30.3%-31.1pp | 0.8% |
| Return on Equity | 3.9%-4.2pp | 8.1%+3.3pp | 4.7%+2.1pp | 2.6%-1.4pp | 4.0%+1.3pp | 2.6%+24.3pp | -21.7%-22.1pp | 0.5% |
| Return on Assets | 1.5%-1.8pp | 3.3%+1.4pp | 1.9%+0.8pp | 1.0%-0.4pp | 1.4%+0.5pp | 0.9%+8.6pp | -7.7%-7.9pp | 0.2% |
| Current Ratio | 1.66-0.2 | 1.83+0.0 | 1.80-0.0 | 1.81+0.3 | 1.47+0.1 | 1.42+0.0 | 1.38-0.3 | 1.72 |
| Debt-to-Equity | 0.66+0.0 | 0.65-0.1 | 0.70-0.0 | 0.75-0.1 | 0.80-1.0 | 1.84+0.0 | 1.82+0.3 | 1.53 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Pediatrix Medical Group, Inc.'s annual revenue?
Pediatrix Medical Group, Inc. (MD) reported $1.9B in total revenue for fiscal year 2025. This represents a -4.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Pediatrix Medical Group, Inc.'s revenue growing?
Pediatrix Medical Group, Inc. (MD) revenue declined by 4.9% year-over-year, from $2.0B to $1.9B in fiscal year 2025.
Is Pediatrix Medical Group, Inc. profitable?
Yes, Pediatrix Medical Group, Inc. (MD) reported a net income of $165.4M in fiscal year 2025, with a net profit margin of 8.6%.
What is Pediatrix Medical Group, Inc.'s EBITDA?
Pediatrix Medical Group, Inc. (MD) had EBITDA of $230.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Pediatrix Medical Group, Inc. have?
As of fiscal year 2025, Pediatrix Medical Group, Inc. (MD) had $375.2M in cash and equivalents against $570.5M in long-term debt.
What is Pediatrix Medical Group, Inc.'s operating margin?
Pediatrix Medical Group, Inc. (MD) had an operating margin of 10.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Pediatrix Medical Group, Inc.'s net profit margin?
Pediatrix Medical Group, Inc. (MD) had a net profit margin of 8.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Pediatrix Medical Group, Inc.'s return on equity (ROE)?
Pediatrix Medical Group, Inc. (MD) has a return on equity of 19.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Pediatrix Medical Group, Inc.'s operating cash flow?
Pediatrix Medical Group, Inc. (MD) generated $271.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Pediatrix Medical Group, Inc.'s total assets?
Pediatrix Medical Group, Inc. (MD) had $2.2B in total assets as of fiscal year 2025, including both current and long-term assets.
What is Pediatrix Medical Group, Inc.'s current ratio?
Pediatrix Medical Group, Inc. (MD) had a current ratio of 1.66 as of fiscal year 2025, which is generally considered healthy.
What is Pediatrix Medical Group, Inc.'s debt-to-equity ratio?
Pediatrix Medical Group, Inc. (MD) had a debt-to-equity ratio of 0.66 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Pediatrix Medical Group, Inc.'s return on assets (ROA)?
Pediatrix Medical Group, Inc. (MD) had a return on assets of 7.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Pediatrix Medical Group, Inc.'s Altman Z-Score?
Pediatrix Medical Group, Inc. (MD) has an Altman Z-Score of 2.03, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Pediatrix Medical Group, Inc.'s Piotroski F-Score?
Pediatrix Medical Group, Inc. (MD) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Pediatrix Medical Group, Inc.'s earnings high quality?
Pediatrix Medical Group, Inc. (MD) has an earnings quality ratio of 1.64x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Pediatrix Medical Group, Inc. cover its interest payments?
Pediatrix Medical Group, Inc. (MD) has an interest coverage ratio of 5.8x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Pediatrix Medical Group, Inc.?
Pediatrix Medical Group, Inc. (MD) scores 49 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.